An experimental drug originally developed for Alzheimer's disease has shown potential benefits for treating alcohol withdrawal symptoms, according to new research findings.

The drug appears to calm brain inflammation that occurs during alcohol withdrawal, researchers reported. This anti-inflammatory effect could potentially reduce both neural damage and the risk of relapse in people recovering from alcohol dependency.

The research represents an early-stage investigation into repurposing existing pharmaceutical compounds for new medical applications. Scientists have been exploring how medications developed for neurodegenerative diseases might address other conditions involving brain inflammation.

Alcohol withdrawal can cause significant inflammation in brain tissue, leading to complications that may contribute to relapse rates and long-term cognitive effects. The experimental treatment targets these inflammatory processes directly.

The findings are preliminary and further research would be needed to establish the drug's safety and efficacy for alcohol withdrawal treatment. Clinical trials would be required before any potential therapeutic application could be considered for broader use.